| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| NEUTRAL | SELL | SELL | NEUTRAL | BUY |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 246.65▲ | 246.85▼ | 246.85▼ | 247.96▼ | 246.70▼ |
| MA10 | 246.46▲ | 246.31▲ | 246.97▼ | 248.03▼ | 241.42▲ |
| MA20 | 246.73▲ | 249.35▼ | 250.10▼ | 247.59▼ | 238.70▲ |
| MA50 | 248.29▼ | 249.90▼ | 248.80▼ | 242.32▲ | 232.86▲ |
| MA100 | 250.82▼ | 248.88▼ | 248.64▼ | 237.41▲ | 225.02▲ |
| MA200 | 248.00▼ | 248.40▼ | 244.28▲ | 233.16▲ | 216.69▲ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | 0.181▲ | -0.305▼ | -0.617▼ | -0.395▼ | 0.588▲ |
| RSI | 48.502▼ | 42.470▼ | 44.815▼ | 50.419▲ | 55.457▲ |
| STOCH | 36.558 | 48.420 | 27.849 | 56.928 | 69.807 |
| WILL %R | -62.963 | -69.809 | -76.237▼ | -53.703 | -27.194 |
| CCI | 41.617 | -24.804 | -44.488 | -39.370 | 71.998 |
|
Friday, May 08, 2026 09:51 AM
ALX Oncology (NASDAQ:ALXO) executives used the company’s first-quarter 2026 earnings call to highlight new clinical data for its lead CD47 blocker, evorpacept, and to provide updates on its ...
|
|
Friday, May 08, 2026 05:11 AM
Data from Phase 1b/2 trial of evorpacept + zanidatamab presented at ESMO Breast Cancer 2026 showed all patients with confirmed HER2-positive disease and high CD47 expression experienced durable respon ...
|
|
Thursday, May 07, 2026 05:14 AM
Data from Phase 1b/2 trial presented at ESMO Breast Cancer 2026 further validate a biomarker-driven development strategy for evorpacept - - ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 08/05/26 | 245.27 | 248.21 | 245.27 | 246.00 | 34,228 |
| 07/05/26 | 252.80 | 258.1799 | 244.01 | 244.75 | 57,550 |
| 06/05/26 | 252.775 | 255.79 | 250.19 | 253.98 | 33,116 |
| 05/05/26 | 243.21 | 253.525 | 243.21 | 251.27 | 52,878 |
| 04/05/26 | 240.50 | 253.16 | 235.50 | 243.82 | 105,562 |
| 01/05/26 | 251.50 | 251.50 | 241.68 | 244.34 | 48,922 |
| 30/04/26 | 248.28 | 254.02 | 248.28 | 251.96 | 29,554 |
| 29/04/26 | 247.13 | 251.40 | 246.625 | 250.11 | 35,347 |
| 28/04/26 | 247.24 | 249.48 | 239.50 | 249.08 | 19,473 |
| 27/04/26 | 241.66 | 245.81 | 240.01 | 245.01 | 15,953 |
|
|
||||
|
|
||||
|
|